Metabolic network failures in Alzheimer's disease: A biochemical road map

Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium

Research output: Contribution to journalArticle

81 Scopus citations

Abstract

Introduction The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. Methods Fasting serum samples from the Alzheimer's Disease Neuroimaging Initiative (199 control, 356 mild cognitive impairment, and 175 AD participants) were analyzed using the AbsoluteIDQ-p180 kit. Performance was validated in blinded replicates, and values were medication adjusted. Results Multivariable-adjusted analyses showed that sphingomyelins and ether-containing phosphatidylcholines were altered in preclinical biomarker-defined AD stages, whereas acylcarnitines and several amines, including the branched-chain amino acid valine and α-aminoadipic acid, changed in symptomatic stages. Several of the analytes showed consistent associations in the Rotterdam, Erasmus Rucphen Family, and Indiana Memory and Aging Studies. Partial correlation networks constructed for Aβ1–42, tau, imaging, and cognitive changes provided initial biochemical insights for disease-related processes. Coexpression networks interconnected key metabolic effectors of disease. Discussion Metabolomics identified key disease-related metabolic changes and disease-progression-related changes. Defining metabolic changes during AD disease trajectory and its relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.

Original languageEnglish (US)
Pages (from-to)965-984
Number of pages20
JournalAlzheimer's and Dementia
Volume13
Issue number9
DOIs
StatePublished - Sep 2017

Keywords

  • Acylcarnitines
  • Alzheimer's disease
  • Biochemical networks
  • Biomarkers
  • Branched-chain amino acids
  • Dementia
  • Metabolism
  • Metabolomics
  • Metabonomics
  • Pharmacometabolomics
  • Pharmacometabonomics
  • Phospholipids
  • Precision medicine
  • Serum
  • Sphingomyelins
  • Systems biology

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Metabolic network failures in Alzheimer's disease: A biochemical road map'. Together they form a unique fingerprint.

  • Cite this

    Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium (2017). Metabolic network failures in Alzheimer's disease: A biochemical road map. Alzheimer's and Dementia, 13(9), 965-984. https://doi.org/10.1016/j.jalz.2017.01.020